September 13 (Wed), 12:20-13:10, Rm. 401

National OncoVenture, a system-integrated oncology drug development group, was established in June 2011. NOV is a national research and development project group of the Ministry of Health and Welfare supported by National Cancer Center. Our purpose is to carry out the development of oncology drug candidates that were discovered by domestic pharmaceutical companies or academic institutes. NOV aims to develop the candidates into oncology drugs for the global market by providing significant drug development expertise.

The professional project management of new drug development from pre-clinical to clinical development can be done by drug development experts in NOV. We provide the total solution for drug development including funding from the government, research & development support, and business development support, such as global partnering and out-licensing, etc.

Since establishment, NOV have selected 16 competitive oncology drug candidates and are now actively developing nine candidates in clinical and pre-clinical stages. With these efforts, NOV has been able to achieve a number of milestones, including two partnering agreements with global pharmaceutical companies as well as several successful phase 1 and phase 2 human clinical trials in Korea and the US.